查看购物车
  • Traditional Chinese
  • English
  • Japanese
2031 年欧洲生物製剂市场预测 - 区域分析 - 按产品、应用、来源和製造
市场调查报告书
商品编码
1764946

2031 年欧洲生物製剂市场预测 - 区域分析 - 按产品、应用、来源和製造

Europe Biologics Market Forecast to 2031 - Regional Analysis - by Product, Application, Source, and Manufacturing
出版日期: | 出版商: The Insight Partners | 英文 162 Pages | 订单完成后即时交付

价格

2023 年欧洲生物製剂市场价值为 1150.576 亿美元，预计到 2031 年将达到 4154.684 亿美元；预计 2023 年至 2031 年的复合年增长率为 17.4%。

对外包製造业务的偏好推动了欧洲生物製剂市场

生物製剂製造是一个复杂的过程，其成功取决于所有操作的正确执行和监控。製造工厂需要训练有素、具备生物加工和製程工程技术知识的人员。对于经验丰富的团队来说，管理使用手动和开放式製造方法进行首次临床试验，并随后建立更符合商业需求的流程可能并非易事。因此，製造商选择与合约开发和製造组织 (CDMO) 合作，以加速其临床研究和商业化运作。 CDMO 以合约方式为生物製剂公司提供产品开发、临床试验支援、製造和商业化服务。与 CDMO 合作可以为生物製剂製造商提供可扩展性和获取技术专业知识的管道，而无需支付管理费用，同时还能加快产品上市速度并提高成本效益。 2022 年 4 月，ThermoGenesis 在美国加州建立了自己的 CDMO 工厂，为细胞和基因疗法製造商提供 CDMO 服务。该公司凭藉其专业知识，专注于生产嵌合抗原受体T细胞（CAR-T细胞）、T细胞受体（TCR）、肿瘤浸润白血球（TIL）、自然杀手细胞（NK）、诱导多能干细胞（iPSC）和间质干细胞（MSC）。事实证明，将生物製剂生产外包给CDMO对製造商而言具有成本效益。此外，他们还可以利用CDMO先进的技术基础设施和专业知识。 CDMO采用适当的、规划好的流程来生产生物製剂。因此，将生物製剂生产业务外包给CDMO的趋势日益高涨，推动了生物製剂市场的成长。

欧洲生物製剂市场概况

欧洲的生物製剂市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。欧洲拥有第二大市场份额，这可以归因于癌症负担的增加和癌症诊断技术的进步，有助于早期发现。单株抗体在各种研发应用、癌症治疗和免疫疾病中的日益广泛使用也促进了欧洲生物製剂市场的进步。在欧盟所有国家中，德国在医疗保健研究和基础设施方面的投资最大。根据欧盟统计局的数据，2015 年德国的医疗保健支出为 3.949 亿美元，是该地区相关国家中最高的之一。根据 2015 年经合组织卫生统计数据，德国的医疗支出成长速度快于经合组织预测的实际平均值；这可能与为支持药品开发、研究和製造而投入的资本增加有关。因此，对医疗保健产业的强劲资金支持提振了德国的生物製剂市场。

2031年欧洲生物製剂市场营收及预测（百万美元）

欧洲生物製剂市场细分

欧洲生物製剂市场分为产品、应用、来源、製造和国家。

根据产品类型，欧洲生物製剂市场细分为单株抗体、疫苗、重组激素/蛋白质、细胞和基因疗法以及其他。单株抗体在2023年占据了最大的市场。

从应用角度来看，欧洲生物製剂市场主要分为癌症、传染病、自体免疫疾病等。 2023年，癌症领域占据了最大的市场。

从来源来看，欧洲生物製剂市场分为哺乳动物和微生物两大类。 2023年，哺乳动物类生物製剂占了更大的市场。

根据製造方式，欧洲生物製剂市场分为外包和内部製造。 2023年，外包部分占据了更大的市场。

就国家而言，欧洲生物製剂市场分为德国、英国、义大利、法国、西班牙和欧洲其他地区。 2023年，德国占据了欧洲生物製剂市场的主导地位。

AbbVie Inc、辉瑞公司、三星生物製品有限公司、ADMA Biologics, Inc.、无锡生物製品有限公司、Catalent Inc、AGC Biologics AS、阿斯利康公司、安进公司、Nitto Avecia 和 Quality Assistance sa 是欧洲生物製剂市场的一些领先公司。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：欧洲生物製剂市场－关键市场动态

  • 市场驱动因素
    • 慢性病盛行率不断上升
    • 倾向外包製造业务
  • 市场限制
    • 生物製剂成本高
  • 市场机会
    • 基因和细胞治疗在生物製剂领域的进展
  • 未来趋势
    • 企业的策略倡议
  • 驱动因素和限制因素的影响：

第五章：欧洲生物製剂市场分析

  • 2021-2031年欧洲生物製剂市场收入
  • 欧洲生物製剂市场预测分析

第六章：欧洲生物製剂市场分析－依产品

  • 单株抗体
  • 疫苗
  • 重组荷尔蒙/蛋白质
  • 细胞和基因治疗
  • 其他的

第七章：欧洲生物製剂市场分析-按应用

  • 癌症
  • 传染病
  • 自体免疫疾病
  • 其他的

第八章：欧洲生物製剂市场分析－依来源

  • 哺乳动物
  • 微生物

第九章：欧洲生物製剂市场分析－依製造

  • 外包
  • 内部

第十章：欧洲生物製剂市场-国家分析

  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区

第 11 章：产业格局

  • 概述
  • 市场倡议
  • 伙伴关係与合作
  • 其他发展

第十二章：公司简介

  • AbbVie Inc
  • Pfizer Inc
  • Samsung Biologics Co Ltd
  • ADMA Biologics, Inc.
  • WuXi Biologics Inc
  • Catalent Inc
  • AGC Biologics AS
  • AstraZeneca Plc
  • Amgen Inc
  • Nitto Avecia
  • Quality Assistance s.a.

第 13 章：附录

Product Code: BMIRE00031589

The Europe biologics market was valued at US$ 1,15,057.6 million in 2023 and is expected to reach US$ 4,15,468.4 million by 2031; it is estimated to register a CAGR of 17.4% from 2023 to 2031.

Preference for Outsourcing Manufacturing Operations Drives Europe Biologics Market

Biologics manufacturing is a complex process whose success depends on the proper execution and monitoring of all operations. The manufacturing facilities need trained personnel with technical knowledge of bioprocessing and process engineering. Managing the attempts to reach the first clinical trial using a manual and open manufacturing method and then building a more commercially suitable process can be tricky for an experienced team. Thus, manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization operations. CDMOs provide product development, clinical trial support, manufacturing, and commercialization services to biologics companies on a contract basis. Partnering with CDMO enables scalability and access to technical expertise without overhead costs, along with higher speed to market and greater cost efficiencies for biologics manufacturers. In April 2022, ThermoGenesis established its own CDMO facility in California, US, to provide CDMO services to cell and gene therapy manufacturers. Using its expertise, the company focuses on manufacturing chimeric antigen receptor-T cell (CAR-T cell), T-cell receptor (TCR), tumor-infiltrating leukocyte (TIL), natural killer cell (NK), iPSC, and mesenchymal stem cell (MSC). Outsourcing biologics manufacturing to CDMOs proves cost-effective for manufacturers. Additionally, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing biologics. Thus, the surging preference for outsourcing biologics manufacturing operations to CDMOs fuels the biologics market growth.

Europe Biologics Market Overview

The biologics market in Europe is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe holds the second-largest market share, which can be attributed to the increasing cancer burden and technological advancements in cancer diagnostics to aid in early detection. The growing use of monoclonal antibodies in various R&D applications, cancer therapies, and immunological disorders is also contributing to the biologics market progress in Europe. Germany invests significantly in healthcare research and infrastructure among all countries in the European Union (EU). According to Eurostat, the healthcare expenditure in Germany accounted for US$ 394.9 million in 2015, which was one of the highest among the relative countries in the region. According to OECD Health Statistics 2015, health spending in Germany is growing faster than the actual OECD-predicted average; this can be associated with the higher capital investments made to support the development, research, and manufacturing of pharmaceuticals. Thus, the robust financial backing to the healthcare sector bolsters the biologics market in Germany.

Europe Biologics Market Revenue and Forecast to 2031 (US$ Million)

Europe Biologics Market Segmentation

The Europe biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Europe biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Europe biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the Europe biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Europe biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Europe biologics market is segmented into Germany, the UK, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Europe biologics market.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Europe Biologics Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increasing Prevalence of Chronic Diseases
    • 4.1.2 Preference for Outsourcing Manufacturing Operations
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Biologics
  • 4.3 Market Opportunities
    • 4.3.1 Gene and Cell Therapy Advancements in Biologics
  • 4.4 Future Trends
    • 4.4.1 Strategic Initiatives by Companies
  • 4.5 Impact of Drivers and Restraints:

5. Biologics Market - Europe Analysis

  • 5.1 Europe Biologics Market Revenue (US$ Million), 2021-2031
  • 5.2 Europe Biologics Market Forecast Analysis

6. Europe Biologics Market Analysis - by Product

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Overview
    • 6.1.2 Monoclonal Antibodies: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.2 Vaccine
    • 6.2.1 Overview
    • 6.2.2 Vaccine: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.3 Recombinant Hormones/Proteins
    • 6.3.1 Overview
    • 6.3.2 Recombinant Hormones/Proteins: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.4 Cell and Gene Therapy
    • 6.4.1 Overview
    • 6.4.2 Cell and Gene Therapy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Europe Biologics Market Analysis - by Application

  • 7.1 Cancer
    • 7.1.1 Overview
    • 7.1.2 Cancer: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Infectious Diseases
    • 7.2.1 Overview
    • 7.2.2 Infectious Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Autoimmune Diseases
    • 7.3.1 Overview
    • 7.3.2 Autoimmune Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Biologics Market Analysis - by Source

  • 8.1 Mammalian
    • 8.1.1 Overview
    • 8.1.2 Mammalian: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Microbial
    • 8.2.1 Overview
    • 8.2.2 Microbial: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Biologics Market Analysis - by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Overview
    • 9.1.2 Outsourced: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 In-house
    • 9.2.1 Overview
    • 9.2.2 In-house: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Biologics Market - Country Analysis

  • 10.1 Europe
    • 10.1.1 Europe Biologics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Europe Biologics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 Germany: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.2.1 Germany: Europe Biologics Market Share - by Product
        • 10.1.1.2.2 Germany: Europe Biologics Market Share - by Application
        • 10.1.1.2.3 Germany: Europe Biologics Market Share - by Source
        • 10.1.1.2.4 Germany: Europe Biologics Market Share - by Manufacturing
      • 10.1.1.3 United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.3.1 United Kingdom: Europe Biologics Market Share - by Product
        • 10.1.1.3.2 United Kingdom: Europe Biologics Market Share - by Application
        • 10.1.1.3.3 United Kingdom: Europe Biologics Market Share - by Source
        • 10.1.1.3.4 United Kingdom: Europe Biologics Market Share - by Manufacturing
      • 10.1.1.4 Italy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.4.1 Italy: Europe Biologics Market Share - by Product
        • 10.1.1.4.2 Italy: Europe Biologics Market Share - by Application
        • 10.1.1.4.3 Italy: Europe Biologics Market Share - by Source
        • 10.1.1.4.4 Italy: Europe Biologics Market Share - by Manufacturing
      • 10.1.1.5 France: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.5.1 France: Europe Biologics Market Share - by Product
        • 10.1.1.5.2 France: Europe Biologics Market Share - by Application
        • 10.1.1.5.3 France: Europe Biologics Market Share - by Source
        • 10.1.1.5.4 France: Europe Biologics Market Share - by Manufacturing
      • 10.1.1.6 Spain: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.6.1 Spain: Europe Biologics Market Share - by Product
        • 10.1.1.6.2 Spain: Europe Biologics Market Share - by Application
        • 10.1.1.6.3 Spain: Europe Biologics Market Share - by Source
        • 10.1.1.6.4 Spain: Europe Biologics Market Share - by Manufacturing
      • 10.1.1.7 Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.7.1 Rest of Europe: Europe Biologics Market Share - by Product
        • 10.1.1.7.2 Rest of Europe: Europe Biologics Market Share - by Application
        • 10.1.1.7.3 Rest of Europe: Europe Biologics Market Share - by Source
        • 10.1.1.7.4 Rest of Europe: Europe Biologics Market Share - by Manufacturing

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Market Initiative
  • 11.3 Partnerships and Collaborations
  • 11.4 Other Developments

12. Company Profiles

  • 12.1 AbbVie Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Pfizer Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Samsung Biologics Co Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 ADMA Biologics, Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 WuXi Biologics Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Catalent Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AGC Biologics AS
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 AstraZeneca Plc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Amgen Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Nitto Avecia
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Quality Assistance s.a.
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments

13. Appendix

  • 13.1 About Us

List Of Tables

  • Table 1. Europe Biologics Market Segmentation
  • Table 2. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Product
  • Table 4. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Application
  • Table 5. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Source
  • Table 6. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Manufacturing
  • Table 7. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 9. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 10. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 11. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 12. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 13. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 14. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 15. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 16. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 17. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 18. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 19. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 20. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 21. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 22. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 23. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 24. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 25. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 26. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 27. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 28. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 29. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 30. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 31. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing

List Of Figures

  • Figure 1. Europe Biologics Market Segmentation - Country
  • Figure 2. Europe Biologics Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Biologics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Europe Biologics Market Share (%) - by Product (2023 and 2031)
  • Figure 6. Monoclonal Antibodies: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Vaccine: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Recombinant Hormones/Proteins: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Cell and Gene Therapy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Europe Biologics Market Share (%) - by Application (2023 and 2031)
  • Figure 12. Cancer: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Infectious Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Autoimmune Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Europe Biologics Market Share (%) - by Source (2023 and 2031)
  • Figure 17. Mammalian: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Microbial: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Europe Biologics Market Share (%) - by Manufacturing (2023 and 2031)
  • Figure 20. Outsourced: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. In-house: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Europe Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. Germany: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. Italy: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. France: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 27. Spain: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 28. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)